公开(公告)号：WO2015085238A1

公开(公告)日：2015-06-11

申请号：PCT/US2014/068906

申请日：2014-12-05

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION

Inventor： COHEN, Seth M. ,  PUERTA, David T. ,  PEREZ, Christian

IPC: A61K31/35 ,  A61K31/4412 ,  A61P31/04

CPC classification number: C07D309/40 ,  C07D213/69 ,  C07D213/70 ,  C07D213/81 ,  C07D309/36 ,  C07D405/06

Abstract: Provided herein, inter alia , are compounds and methods for treating infectious diseases. The compounds provided herein are, inter alia , useful for the treatment of bacterial infections. The compounds provided herein are, inter alia, useful inhibitors of metalloproteins, e.g. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC).

Abstract translation: 特别地，本文提供了用于治疗感染性疾病的化合物和方法。 本文提供的化合物尤其可用于治疗细菌感染。 本文提供的化合物尤其是金属蛋白的有用抑制剂，例如， UDP-3-O-（R-3-羟基肉豆蔻酰）-N-乙酰葡糖胺脱乙酰酶（LpxC）。

公开(公告)号：WO2015031799A1

公开(公告)日：2015-03-05

申请号：PCT/US2014/053487

申请日：2014-08-29

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION

Inventor： MAKALE, Milan T. ,  WRASIDLO, Wolfgang J. ,  KESARI, Santosh ,  MCKITTRICK, Joanna ,  HIRATA FLORES, Gustavo A. ,  GRAEVE, Olivia

IPC: A61K41/00

CPC classification number: A61K41/0042 ,  A61K31/704 ,  A61K47/48884 ,  A61K47/6923 ,  A61K47/6929 ,  A61N5/06 ,  A61N5/10 ,  A61N2005/0661 ,  A61N2005/1098

Abstract: There are provided, inter alia , compositions including a scintillator nanocrystal linked to a chemical agent moiety through a scintillator-activated photocleavable linker, and methods of use thereof.

Abstract translation: 特别地，提供了包括通过闪烁体激活的可光裂解连接体连接到化学试剂部分的闪烁体纳米晶体的组合物及其使用方法。

公开(公告)号：WO2014165263A1

公开(公告)日：2014-10-09

申请号：PCT/US2014/025016

申请日：2014-03-12

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION ,  TANZI, Rudolph E.

Inventor： TANZI, Rudolph E. ,  WAGNER, Steven L. ,  CHENG, Soan ,  MOBLEY, William C.

IPC: A61K31/4436

CPC classification number: C07D417/14 ,  C07D487/04

Abstract: There are provided, imer alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.

Abstract translation: 尤其提供通过抑制γ-分泌酶的催化活性降低总AB肽产生的化合物和方法。 由于所有主要的AB肽变体（包括本领域已知的致病性AB42）最终都通过APP- C99的γ-分泌酶介导的蛋白水解产生（即，β-分泌酶介导的淀粉样蛋白前体IAPPI的切割产物 ），治疗性干预的一种方法（例如，介入阿尔茨海默氏病，AD）涉及通过抑制γ-分泌酶的催化活性来降低总AB肽的产生。

公开(公告)号：WO2014143643A1

公开(公告)日：2014-09-18

申请号：PCT/US2014/027005

申请日：2014-03-14

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION

Inventor： HOSTETLER, Karl Y. ,  BEADLE, James R. ,  VALIAEVA, Nadejda

IPC: C07F9/40 ,  C07F9/6512 ,  C07F9/6524 ,  A61K31/675 ,  A61K31/662 ,  A61K31/522 ,  A61K31/513 ,  A61P31/12 ,  A61P31/18 ,  A61P31/22 ,  A61P35/00

CPC classification number: A61K31/685 ,  A61K9/0014 ,  A61K9/0031 ,  A61K9/0034 ,  A61K31/675 ,  C07F9/65121 ,  C07F9/65583 ,  C07F9/6561 ,  C07F9/65616 ,  Y02A50/467

Abstract: The present disclosure relates, inter alia , to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.

Abstract translation: 本公开尤其涉及用于治疗病毒性疾病和癌症的组合物和方法。 公开了亲脂性抗病毒和抗癌非环型核苷膦酸二酯，其制备方法和使用该化合物治疗病毒性疾病和癌症的方法。

公开(公告)号：WO2012145746A1

公开(公告)日：2012-10-26

申请号：PCT/US2012/034662

申请日：2012-04-23

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION ,  BENNETT, Jeffrey, L. ,  OWENS, Gregory, P. ,  VERKMAN, Alan, S.

Inventor： BENNETT, Jeffrey, L. ,  OWENS, Gregory, P. ,  VERKMAN, Alan, S.

IPC: A61K39/00 ,  A61P25/00

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention is directed to antibodies binding to aquaporin 4 (AQP4) and methods of using such antibodies to treat neuromyelitis optica (NMO) either as a monotherapy or in combination with standard NMO therapies such as immunosuppressives or plasmaphersis.

Abstract translation: 本发明涉及结合水通道蛋白4（AQP4）的抗体以及使用这种抗体治疗神经性眼炎（NMO）作为单一疗法或与标准NMO疗法如免疫抑制剂或血浆平滑肌病联合使用的方法。

公开(公告)号：WO2014153009A3

公开(公告)日：2014-09-25

申请号：PCT/US2014/028656

申请日：2014-03-14

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION ,  UNIVERSITY COLLEGE DUBLIN

Inventor： OSCARSON, Stefan ,  FAHY, John Vincent ,  YUAN, Shaopeng ,  CARRINGTON, Stephen

IPC: A61K31/10 ,  A61K31/70 ,  A61P11/12

Abstract: There are provided, inter alia , methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Abstract translation: 特别提供了用于减少有需要的受试者的粘液弹性或降低粘液粘度的方法，所述方法包括向受试者施用有效量的 硫糖粘液溶解剂，以及用于该方法的化合物和药物组合物。

公开(公告)号：WO2017070320A1

公开(公告)日：2017-04-27

申请号：PCT/US2016/057869

申请日：2016-10-20

Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ,  NATIONAL INSTITUTES OF HEALTH ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION

Inventor： HURYN, Donna M. ,  WIPF, Peter ,  LAPORTE, Matthew G. ,  COLOMBO, Raffaele ,  KOVALIOV, Marina ,  LIM, Chaemin ,  ALVEREZ, Celeste Natalie ,  YUE, Zhizhou ,  SAMAHKUMARA, Lalith Palitha ,  CHATTERLEY, Alexander Julian ,  YAN, Yongzhao ,  LIANG, Mary ,  GREEN, Neal J. ,  MOORE, William ,  BALDWIN, Eric ,  ARKIN, Michelle R. ,  NEITZ, Jeff ,  BULFER, Stacie ,  ANG, Kean-Hooi ,  BRYANT, Clifford

IPC: C07D401/14 ,  C07D401/10 ,  C07D209/04 ,  A61K31/454 ,  A61K31/496 ,  A61K31/404

CPC classification number: A61K31/404 ,  A61K31/454 ,  A61K31/496 ,  C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14

Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.

Abstract translation: 本发明涉及抑制p97的方法以及用于这些方法的化合物和组合物。 可以用本发明的化合物和组合物治疗的疾病和病症包括但不限于易于通过抑制p97治疗的癌症和神经变性疾病。

公开(公告)号：WO2017066785A1

公开(公告)日：2017-04-20

申请号：PCT/US2016/057390

申请日：2016-10-17

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY ,  SHRINERS HOSPITALS FOR CHILDREN

Inventor： CHO, Kiho ,  GREENHALGH, David ,  CHO, Dong Ho

IPC: C12Q1/68 ,  G06K9/32 ,  G06F19/22 ,  G06F19/24 ,  G06F19/26

CPC classification number: G06F19/26 ,  C12Q1/68 ,  G06F19/22 ,  G06K9/00147

Abstract: Methods for determining a genetic identity of a cell, tissue, organ, or organism, based on type, position, and size of every occurrence of at least one repetitive element in the genome of the cell, tissue, organ, or organism. The methods can include using a computer to generate a graphical representation of the genetic identity of the cell, tissue, organ, or organism, and comparing genetic identity at different times/spaces. Also described herein is a computer implemented Universal Genome Information System, which serves as a genome-RE/TRE information management and analysis platform.

Abstract translation: 根据细胞，组织，基因组中的至少一种重复元件的每次出现的类型，位置和大小确定细胞，组织，器官或生物体的遗传一致性的方法 ，器官或生物体。 所述方法可以包括使用计算机产生细胞，组织，器官或生物体的遗传特性的图形表示，并比较不同时间/空间处的遗传特性。 本文还描述了计算机实现的通用基因组信息系统，其用作基因组-RE / TRE信息管理和分析平台。

公开(公告)号：WO2015027080A2

公开(公告)日：2015-02-26

申请号：PCT/US2014/052127

申请日：2014-08-21

Applicant: NORTHROP GRUMMAN SYSTEMS CORPORATION ,  THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE NAVY ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION

Inventor： HOBART, Karl, D. ,  FEYGELSON, Tatyana, I. ,  IMHOFF, Eugene, A. ,  ANDERSON, Travis, J. ,  CALDWELL, Joshua, D. ,  KOEHLER, Andrew, D. ,  PATE, Bradford, B. ,  TADJER, Marko, J. ,  SANDHU, Rajinder, S. ,  GAMBIN, Vincent ,  LEWIS, Gregory ,  SMORCHKOVA, Ioulia ,  GOORSKY, Mark ,  MCKAY, Jeff

IPC: H01L29/66

CPC classification number: H01L29/66462 ,  H01L21/02115 ,  H01L21/02164 ,  H01L21/0217 ,  H01L21/0254 ,  H01L21/3065 ,  H01L21/31122 ,  H01L21/76802 ,  H01L23/367 ,  H01L23/3677 ,  H01L23/3732 ,  H01L29/1602 ,  H01L29/2003 ,  H01L29/778 ,  H01L2924/0002 ,  H01L2924/00

Abstract: A method for fabricating a semiconductor device, such as a GaN high electron mobility transistor (HEMT) device, including etching a thermal via into a back-side of a semiconductor substrate and depositing a diamond nucleation seed layer across the back-side of the substrate. The method further includes coating the diamond nucleation with a mask layer and removing mask material outside of the thermal via on the planar portions of the back-side of the substrate. The method includes removing portions of the diamond nucleation layer on the planar portions and then removing the remaining portion of the mask material in the thermal via. The method then includes depositing a bulk diamond layer within the thermal via on the remaining portion of the diamond nucleation layer so that diamond only grows in the thermal via and not on the planar portions of the substrate.

Abstract translation: 一种用于制造诸如GaN高电子迁移率晶体管（HEMT）器件的半导体器件的方法，该方法包括：将热通孔蚀刻到半导体衬底的背侧中;以及沉积金刚石成核种子层 穿过衬底的背面。 该方法进一步包括用掩模层涂覆金刚石成核并且在衬底的背侧的平面部分上去除热通孔外部的掩模材料。 该方法包括去除平面部分上的金刚石成核层的部分，然后去除热通孔中的掩模材料的剩余部分。 然后该方法包括在热通孔内在金刚石成核层的剩余部分上沉积体块金刚石层，使得金刚石仅在热通道中生长而不在衬底的平面部分上生长。

公开(公告)号：WO2011143579A2

公开(公告)日：2011-11-17

申请号：PCT/US2011/036464

申请日：2011-05-13

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF UNIVERSITY OF ARIZONA ,  RAJ, Kavitha, P. ,  ZELL, Jason ,  McLAREN, Christine, E. ,  GERNER, Eugene, W. ,  MEYSKENS, Frank, L. ,  JACOB, Jeffrey ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION ,  CANCER PREVENTION PHARMACEUTICALS, INC.

Inventor： RAJ, Kavitha, P. ,  ZELL, Jason ,  McLAREN, Christine, E. ,  GERNER, Eugene, W. ,  MEYSKENS, Frank, L. ,  JACOB, Jeffrey

IPC: A61K31/195 ,  A61K31/198 ,  A61K31/355 ,  A61K31/13 ,  A61P35/00

CPC classification number: A61K31/198 ,  A61K31/13 ,  A61K31/192 ,  A61K31/195 ,  A61K31/355 ,  A61K31/415 ,  A61K45/06 ,  A61K2300/00

Abstract: Controlling exogenous polyamines may be used, in some aspects, as an adjunctive strategy to chemoprevention with polyamine inhibitory agents, for example, anti-carcinoma combination therapies comprising ornithine decarboxylase (ODC) inhibitor and a spermidine/spermine N 1 -acetyltransferase expression agonist, optionally based on a patient's ODC1 promoter genotype. Assessing a tissue polyamine level or tissue polyamine flux may be used in some aspects, for predicting the efficacy of an anti-carcinoma combination therapy comprising, for example, an ornithine decarboxylase (ODC) inhibitor and an agent that modulates the polyamine pathway to reduce overall cellular polyamine content.

Abstract translation: 在某些方面，可以使用控制外源多胺作为与多胺抑制剂进行化学预防的辅助策略，例如包括鸟氨酸脱羧酶（ODC）抑制剂和亚精胺/精胺N 1 - 乙酰基转移酶表达激动剂的抗癌联合疗法，任选地 基于患者的ODC1启动子基因型。 在一些方面可以使用组织多胺水平或组织多胺通量的评估，以预测包括例如鸟氨酸脱羧酶（ODC）抑制剂和调节多胺途径以降低整体的药物的抗癌联合疗法的功效 细胞多胺含量。